Orencia Launch Anticipated By Bristol In Early 2006

Bristol-Myers Squibb expects to gain approval for its rheumatoid arthritis therapy Orencia "soon" and plans to launch the biologic in early 2006, CEO Peter Dolan said during the company's third quarter sales and earnings call Oct. 28